T-group (topology)
1.1.1 acid protease
Ligands and drugs
10,007
Member domains
4,546
with ligand contacts (≤ 4 Å)
45.4% of members
4,507
with DrugDomain annotations
45.0% of members
2,454
with a DrugBank compound
24.5% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 1.1.1 belongs to X-group 1 cradle loop barrel, which binds 9.4 ligand superclasses per 20 proteins, broader than 87% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 164 |
| DB01264 | 017 | Darunavir | 161 |
| DB02078 | PG5 | Triglyme | 88 |
| DB01232 | ROC | Saquinavir | 65 |
| DB00701 | 478 | Amprenavir | 54 |
| DB09459 | TLA | L-tartaric acid | 51 |
| DB03345 | BME | Mercaptoethanol | 37 |
| DB00224 | MK1 | Indinavir | 36 |
| DB00503 | RIT | Ritonavir | 33 |
| DB01601 | AB1 | Lopinavir | 27 |
| DB01694 | TAR | D-tartaric acid | 26 |
| DB00220 | 1UN | Nelfinavir | 24 |
| DB01072 | DR7 | Atazanavir | 24 |
| DB00932 | TPV | Tipranavir | 20 |
| DB03904 | URE | Urea | 14 |
| DB02668 | JE2 | JE-2147 | 10 |
| DB02676 | B3P | 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol | 10 |
| DB02702 | XV6 | XV638 | 8 |
| DB12285 | 66F | Verubecestat | 8 |
| DB03843 | FOR | Formaldehyde | 7 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 439 |
| NAmetal | SODIUM ION | 200 |
| 017 | (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | 161 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 144 |
| IOD | IODIDE ION | 143 |
| PG5 | 1-METHOXY-2-[2-(2-METHOXY-ETHOXY]-ETHANE | 88 |
| U1H | [4-(trifluoromethyl)phenyl]methanamine | 78 |
| ZNmetal | ZINC ION | 78 |
| ROC | (2S)-N-[(2S,3R)-4-[(2S,3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenyl-butan-2-yl]-2-(quinolin-2-ylcarbonylamino)butanediamide | 63 |
| TLA | L(+)-TARTARIC ACID | 58 |
| 478 | {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL-2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL ESTER | 55 |
| 2NC | N-{(2S)-2-[(N-acetyl-L-threonyl-L-isoleucyl)amino]hexyl}-L-norleucyl-L-glutaminyl-N~5~-[amino(iminio)methyl]-L-ornithinamide | 54 |
| 3TL | benzyl [(1S,4S,7S,8R,9R,10S,13S,16S)-7,10-dibenzyl-8,9-dihydroxy-1,16-dimethyl-4,13-bis(1-methylethyl)-2,5,12,15,18-pentaoxo-20-phenyl-19-oxa-3,6,11,14,17-pentaazaicos-1-yl]carbamate | 42 |
| 0Q4 | N-[(2R)-2-({N~5~-[amino(iminio)methyl]-L-ornithyl-L-valyl}amino)-4-methylpentyl]-L-phenylalanyl-L-alpha-glutamyl-L-alanyl-L-norleucinamide | 40 |
| BME | BETA-MERCAPTOETHANOL | 37 |
| MK1 | N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARYBUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE | 36 |
| RIT | RITONAVIR | 33 |
| TAR | D(-)-TARTARIC ACID | 31 |
| AB1 | N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE | 27 |
| 1UN | 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE | 24 |